UPM, a division of Gregory Pharmaceutical Holdings, Inc., has entered an agreement with Amerigen Pharmaceuticals, Inc. to manufacture two ANDA products for a 10- year commercial supply term. Also, UPM may potentially develop and supply several additional ANDA products for Amerigen under the agreement.
Back in July 2013, UPM acquired Pfizer’s 475,000 sq.-ft. manufacturing facility in Bristol, TN, which is where all of these products will eventually be made.
Dr. John M. Gregory, chairman and chief executive officer of Gregory Pharmaceutical Holdings, Inc., said, "UPM has been working with Amerigen for the past three years. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients."
Jonathan Embleton, chief business officer of Amerigen, said, "Amerigen looks forward to a long relationship with UPM. We are excited about our upcoming product portfolio and the role UPM will play in providing products to market."